An Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.
- 11 Jan 2018 Planned initiation date changed from 21 Nov 2017 to 1 Mar 2018.
- 04 Nov 2017 New trial record